ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Kyntra Bio, Qilu Pharmaceutical and Biocad side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Kyntra Bio×Qilu Pharmaceutical×Biocad×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Kyntra BioQilu PharmaceuticalBiocad
studies on the registry4121994
open to participants now213612
phase 3 studies under way15315
reach primary completion within a year0504
programswith a study of their own in two years27210

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseKyntra BioQilu PharmaceuticalBiocad
Phase 100%

Qilu Pharmaceutical: 24 of its 72 programs at phase 1

  1. apripitant and palonosetron injectable emulsionphase 1
  2. follitropin alfaphase 1
  3. Meropenem-Pralubactamphase 1
  4. QL2302phase 1
  5. QLF4113phase 1

and 19 more — sign in to see them all

33%

Biocad: 2 of its 10 programs at phase 1

  1. BCD-256phase 1
  2. BCD-261phase 1
20%
Phase 2

Kyntra Bio: 1 of its 2 programs at phase 2

  1. Anti-CD46 Antibody-drug Conjugate FOR46phase 2
50%

Qilu Pharmaceutical: 14 of its 72 programs at phase 2

  1. QLS1410phase 2
  2. QLS12010phase 2
  3. KRAS G12D Inhibitor QLC1101phase 2
  4. QLH12016phase 2
  5. QLC1401phase 2

and 9 more — sign in to see them all

19%

Biocad: 2 of its 10 programs at phase 2

  1. anti-TL1A monoclonal antibody, low dosephase 2
  2. BCD-236phase 2
20%
Phase 300%

Qilu Pharmaceutical: 32 of its 72 programs at phase 3

  1. Iparomlimab/Tuvonralimabphase 3
  2. QLC5508phase 3
  3. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3
  4. QL2107phase 3
  5. QLC7401phase 3

and 27 more — sign in to see them all

44%

Biocad: 6 of its 10 programs at phase 3

  1. divozilimabphase 3
  2. BCD-248phase 3
  3. pegdarbepoetin betaphase 3
  4. BCD-281phase 3
  5. Adalimumabphase 3

and 1 more — sign in to see them all

60%
Approved, new studies

Kyntra Bio: 1 of its 2 programs at approved, new studies

  1. roxadustatapproved, new study
50%

Qilu Pharmaceutical: 2 of its 72 programs at approved, new studies

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study
  2. Tafamidis Meglumine Soft Capsulesapproved, new study
3%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Kyntra Bio0 readouts · 0 phase 3············
Qilu Pharmaceutical37 readouts · 13 phase 3

Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion

  1. apripitant and palonosetron injectable emulsionphase 1 · Nov 0 · NCT07817004
  2. QLS1304phase 2 · Nov 0 · NCT06823609

Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3 · Dec 0 · NCT06942767
  2. pralurbactamphase 3 · Dec 0 · NCT07089186
  3. QL1207Hphase 3 · Dec 0 · NCT07489586
  4. QL2107phase 3 · Dec 0 · NCT06754644
  5. QLG1091phase 3 · Dec 0 · NCT07487103

and 4 more — sign in to see them all

Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QL1206phase 3 · Jan 0 · NCT07062978
  2. QLS1510phase 1 · Jan 30 · NCT07760077

Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. QLC1401phase 2 · Feb 0 · NCT07173556

Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLH2405phase 1 · Mar 0 · NCT07489599
  2. QLM3003phase 3 · Mar 0 · NCT06880276

Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-HER2 Monoclonal Antibody QL1209phase 3 · Apr 0 · NCT07861139
  2. Platinum Compoundsphase 2 · Apr 0 · NCT07453394
  3. QLS1209phase 1 · Apr 0 · NCT06872580
  4. QLS5132phase 3 · Apr 0 · NCT07453394
  5. QL0911phase 3 · Apr 30 · NCT06456528

Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-B7-H3 Antibody-drug Conjugate MHB088Cphase 3 · May 0 · NCT06954246
  2. daprodustatphase 3 · May 0 · NCT07300111
  3. QL2108phase 3 · May 0 · NCT06884891
  4. QLG2128phase 3 · May 0 · NCT06898060

Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3 · Jun 0 · NCT06732323
  2. Iparomlimab/Tuvonralimabphase 3 · Jun 0 · NCT07272590
  3. QL2401phase 2 · Jun 0 · NCT07620366
  4. QLC5513phase 2 · Jun 0 · NCT07272590
  5. QLS5308phase 1 · Jun 0 · NCT07462442

and 2 more — sign in to see them all

Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion

  1. QLS5133phase 2 · Jul 0 · NCT07061639

Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion

  1. QLS2406-1 injectionphase 1 · Aug 30 · NCT07937787
·

Qilu Pharmaceutical, Oct ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. QLC7401phase 3 · Oct 7 · NCT07444086
  2. QLS2312phase 1 · Oct 9 · NCT07861581
  3. QLS7402 Injectionphase 1 · Oct 29 · NCT07950462
Biocad1 readouts · 0 phase 3··

Biocad, Jan ’27: 1 program whose next study reaches primary completion

  1. anti-TL1A monoclonal antibody, low dosephase 2 · Jan 0 · NCT07080034
·········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Kyntra Bio

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Qilu Pharmaceutical

New programs 7

Reached a new phase 2

  • QLS4131phase 3 · Nov 6 · Multiple Myeloma
  • QLS5132phase 3 · Oct 20 · Carcinoma, Ovarian Epithelial

Study stopped 0

None

Primary completion later 1

Biocad

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionKyntra BioQilu PharmaceuticalBiocad
Multiple Myelomaall three · compare here

Kyntra Bio in Multiple Myeloma: 1 program

  1. Anti-CD46 Antibody-drug Conjugate FOR46phase 2

Their studies: Kyntra Bio’s studies of Multiple Myeloma in search

Qilu Pharmaceutical in Multiple Myeloma: 4 programs

  1. QL2109phase 3
  2. QLS4131phase 3
  3. QLS32015phase 3
  4. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Multiple Myeloma in search

Biocad in Multiple Myeloma: 1 program

  1. BCD-248phase 3

Their studies: Biocad’s studies of Multiple Myeloma in search

Anemiaall three · compare here

Kyntra Bio in Anemia: 1 program

  1. roxadustatapproved, new study

Their studies: Kyntra Bio’s studies of Anemia in search

Qilu Pharmaceutical in Anemia: 1 program

  1. daprodustatphase 3

Their studies: Qilu Pharmaceutical’s studies of Anemia in search

Biocad in Anemia: 1 program

  1. pegdarbepoetin betaphase 3

Their studies: Biocad’s studies of Anemia in search

Prostatic Neoplasms2 of 3 · compare here

Kyntra Bio in Prostatic Neoplasms: 1 program

  1. Anti-CD46 Antibody-drug Conjugate FOR46phase 2

Their studies: Kyntra Bio’s studies of Prostatic Neoplasms in search

Qilu Pharmaceutical in Prostatic Neoplasms: 5 programs

  1. QLC5508phase 3
  2. QLG1080phase 3
  3. QLH12016phase 2
  4. QLF4113phase 1
  5. QLS2401phase 1

Their studies: Qilu Pharmaceutical’s studies of Prostatic Neoplasms in search

–
Arthritis, Rheumatoid2 of 3 · compare here–

Qilu Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Biocad in Arthritis, Rheumatoid: 1 program

  1. Adalimumabphase 3

Their studies: Biocad’s studies of Arthritis, Rheumatoid in search

Hidradenitis Suppurativa2 of 3 · compare here–

Qilu Pharmaceutical in Hidradenitis Suppurativa: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Hidradenitis Suppurativa in search

Biocad in Hidradenitis Suppurativa: 1 program

  1. Adalimumabphase 3

Their studies: Biocad’s studies of Hidradenitis Suppurativa in search

Multiple Sclerosis2 of 3 · compare here–

Qilu Pharmaceutical in Multiple Sclerosis: 1 program

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study

Their studies: Qilu Pharmaceutical’s studies of Multiple Sclerosis in search

Biocad in Multiple Sclerosis: 1 program

  1. divozilimabphase 3

Their studies: Biocad’s studies of Multiple Sclerosis in search

Myelodysplastic Syndromes2 of 3 · compare here

Kyntra Bio in Myelodysplastic Syndromes: 1 program

  1. roxadustatapproved, new study

Their studies: Kyntra Bio’s studies of Myelodysplastic Syndromes in search

Qilu Pharmaceutical in Myelodysplastic Syndromes: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Myelodysplastic Syndromes in search

–
Psoriasis2 of 3 · compare here–

Qilu Pharmaceutical in Psoriasis: 1 program

  1. QL2106phase 3

Their studies: Qilu Pharmaceutical’s studies of Psoriasis in search

Biocad in Psoriasis: 1 program

  1. Adalimumabphase 3

Their studies: Biocad’s studies of Psoriasis in search

Triple Negative Breast Neoplasms2 of 3 · compare here–

Qilu Pharmaceutical in Triple Negative Breast Neoplasms: 1 program

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3

Their studies: Qilu Pharmaceutical’s studies of Triple Negative Breast Neoplasms in search

Biocad in Triple Negative Breast Neoplasms: 1 program

  1. BCD-236phase 2

Their studies: Biocad’s studies of Triple Negative Breast Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetKyntra BioQilu PharmaceuticalBiocad
EGLN1roxadustatruledaprodustatrule–
EGLN2roxadustatruledaprodustatrule–
EGLN3roxadustatruledaprodustatrule–
P4HTMroxadustatruledaprodustatrule–
A target, or a pathogen for a vaccine, known for: Kyntra Bio 2 of 2 · Qilu Pharmaceutical 18 of 72 · Biocad 2 of 10 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.